AGN 241689Alternative Names: AGN-241689
Latest Information Update: 12 Nov 2016
At a glance
- Originator Allergan
- Class Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Migraine
Most Recent Events
- 01 Sep 2016 Phase-II/III clinical trials in Migraine (Prevention) in USA (PO)
- 24 Aug 2016 Allergan plans a phase II/III trial for Migraine (Prevention) in USA (NCT02848326)